Advertisement

Treatment of Rheumatoid Arthritis With Zinc Sulfate

  • Peter A. Simkin
Chapter
Part of the Experimental Biology and Medicine book series (EBAM, volume 2)

Abstract

Before I review the present status of oral zinc supplements in rheumatoid arthritis, I believe it is appropriate to briefly describe this disease and the accepted approach used in evaluating new therapeutic agents. Rheumatoid arthritis is a chronic inflammatory disease primarily affecting the joints but often also attacking additional organ systems. The illness is best recognized by a symmetrical pattern of inflamed peripheral joints which ultimately may become deformed and destroyed. Because the disease characteristically fluctuates, it is not possible to distinguish between spontaneous remissions and those induced by therapy in individual patients. Because the etiology is unknown, all therapeutic agents are empirical and suppressive rather than curative in nature.

Keywords

Rheumatoid Arthritis Psoriatic Arthritis Zinc Deficiency Zinc Supplement Serum Zinc 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P.A. Simkin, Lancet, II, 539 (1976).CrossRefGoogle Scholar
  2. 2.
    S.N. Desai, Personal communication,Google Scholar
  3. 3.
    C.J. Menkes, Ch. Job, F. Delbarre, Nouv. Presse Med., 7, 760 (1978).PubMedGoogle Scholar
  4. 4.
    Ch. Job, C.J. Menkes, A. De Gery, H. Brouilhet, and F. Delbarre, in “Histidine II; Laboratory and Clinical Aspects - Therapeutic Use of Histidine and Zinc, G Partsch, and S. Batsford, Eds,, George Thieme Verlag, Stuttgart, 1980, p. 71 ff.Google Scholar
  5. 5.
    O.J. Clemmensen, J. Siggaard-Andersen, A.M. Worm, D. Stahl, F. Frost and I. Bloch, Br. J. Dermatol., 100, 411 (1980).CrossRefGoogle Scholar
  6. 6.
    R.C. Mattingly and A.G Mowat (Presentation at 15th International Congress of Rheumatology, Paris, June, 1981 ).Google Scholar
  7. 7.
    A.C. Kennedy, R.G. Bessent, P. Davis and P.M.G. Reynolds, Br. J. Nutr., 40, 115 (1978).PubMedCrossRefGoogle Scholar
  8. 8.
    W. Niedermeier and J.H. Griggs, J. Chron. Dis., 23, 527 (1971).PubMedCrossRefGoogle Scholar
  9. 9.
    J.R.J.Sorenson, Inorg. Perspectives Biol. Med., 2, 1 (1978).Google Scholar
  10. 10.
    D.M. Grennan, J.M.L. Knudson, M.J. MacKinnon, D.B. Myers, and D.G. Palmer, NZ Med. J., 21, 47 (1980).Google Scholar
  11. 11.
    Z. Balogh, A.F. El-Ghobarey, G.S. Fell, D.H. Brown, J. Dunlop, and W.C. Dick, Ann. Rheum. Dis., 39, 329 (1980)PubMedCrossRefGoogle Scholar
  12. 12.
    P.A. Simkin, Agents Actions, 8, 587 (1981).Google Scholar
  13. 13.
    R.A. Bonebrake, J.T. McCall, G.G. Hunder, and H.F. Polley, Mayo Clin. Proc., 47, 746 (1972).PubMedGoogle Scholar
  14. 14.
    U. Ambanelli, G.F. Ferraccioli, P. Bernardi, and G. Serventi, J. Rheumatol., 5. 477 (1978).PubMedGoogle Scholar
  15. 15.
    A.C. Kennedy, G.S. Fell, P.J. Rooney, W.H. Stevens, W.C. Dick, and W.W. Buchanan, Scand. J. Rheumatol., 4, 243 (1975).PubMedCrossRefGoogle Scholar
  16. 16.
    C. Mery, F. Delrieu, R. Ghozlan, L. Saporta, F. Simon, B. Amor, C.J. Menkes and F. Delbarre, Scand. J. Rheumatol., 5, 241 (1976).PubMedCrossRefGoogle Scholar
  17. 17.
    J. Duchateau, G. Delepesse, R. Vrijens, and H. Collet, Am. J. Med., 70. 1001 (1981).PubMedCrossRefGoogle Scholar
  18. 18.
    A.C. Kennedy, R.G. Bessent, and P.M.G. Reynolds, J. Rheumatol., 7, 639 (1980).PubMedGoogle Scholar

Copyright information

© The Humana Press Inc. 1982

Authors and Affiliations

  • Peter A. Simkin
    • 1
  1. 1.Division of RheumatologyUniv. of WashingtonSeattleUSA

Personalised recommendations